Literature DB >> 10683620

Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness?

A Dalmau1, B Bergman, B Brismar.   

Abstract

We have studied the occurrence of dual diagnoses (psychoses as well as abuse of either amphetamine, cannabis or opiates) during a 15-year period, among patients treated at Huddinge Hospital, Stockholm, Sweden. The purpose of the study is to evaluate if the different drugs were coupled to different rates of psychiatric co-morbidity. During the period in question, 461, 425 and 371 different patients respectively had been admitted at least once due to dependency on amphetamine, cannabis and opiates. Approximately 30% of the patients with a pure abuse of amphetamine or cannabis and less than 6% of the opiate abusers had been diagnosed at least once with any of the psychoses studied. Comparing the frequency of psychoses among mixed and pure abusers of illegal drugs, with and without a concomitant abuse of alcohol, we found that the co-morbidity rate for mixed opiate abusers increased significantly from 7.2 to 20.2% when alcohol abuse was also present. For abusers of amphetamine and cannabis (both pure and mixed), no differences in co-morbidity rates were seen when an abuse of alcohol was added to that of the drugs. It is difficult to find an explanation for the significant difference between the co-morbidity of pure abuse of amphetamine or cannabis on the one hand and opiates on the other. In conclusion, our findings show that the distribution of psychotic illness is high among abusers of amphetamine and cannabis, in contrast to the generally lower co-morbidity among abusers of opiates. Although these findings are consistent with earlier studies that have shown a propensity for developing psychoses among abusers of amphetamine and cannabis, one should bear in mind that this study is based on inpatients, and is not necessarily representative for all abusers of the drugs in question.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10683620     DOI: 10.1016/s0924-9338(99)00234-5

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  16 in total

Review 1.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

2.  [Substance use associated disorders: frequency in patients with schizophrenic and affective psychoses].

Authors:  L Hermle; R Szlak-Rubin; K L Täschner; P Peukert; A Batra
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

3.  The prevalence of substance use disorders and psychiatric disorders as a function of psychotic symptoms.

Authors:  William V Lechner; Jennifer Dahne; Kevin W Chen; Alison Pickover; Jessica M Richards; Stacey B Daughters; C W Lejuez
Journal:  Drug Alcohol Depend       Date:  2013-01-03       Impact factor: 4.492

4.  Late HIV Testing in a Cohort of HIV-Infected Patients in Puerto Rico.

Authors:  Katherine Y Tossas-Milligan; Robert F Hunter-Mellado; Angel M Mayor; Diana M Fernández-Santos; Mark S Dworkin
Journal:  P R Health Sci J       Date:  2015-09       Impact factor: 0.705

5.  Secondary psychoses: an update.

Authors:  Matcheri S Keshavan; Yoshio Kaneko
Journal:  World Psychiatry       Date:  2013-02       Impact factor: 49.548

6.  Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors.

Authors:  Taiwo Akindipe; Don Wilson; Dan J Stein
Journal:  Metab Brain Dis       Date:  2014-02-16       Impact factor: 3.584

7.  Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network.

Authors:  Daniel J Pilowsky; Li-Tzy Wu; Bruce Burchett; Dan G Blazer; George E Woody; Walter Ling
Journal:  Subst Abuse Rehabil       Date:  2011-01-01

8.  Buprenorphine maintenance program with contracted work/education and low tolerance for non-prescribed drug use: a cohort study of outcome for women and men after seven years.

Authors:  Leif Öhlin; Mats Fridell; Anna Nyhlén
Journal:  BMC Psychiatry       Date:  2015-03-24       Impact factor: 3.630

9.  Attention deficit/hyperactivity disorders with co-existing substance use disorder is characterized by early antisocial behaviour and poor cognitive skills.

Authors:  Berit Bihlar Muld; Jussi Jokinen; Sven Bölte; Tatja Hirvikoski
Journal:  BMC Psychiatry       Date:  2013-12-13       Impact factor: 3.630

10.  Excessive substance use in bipolar disorder is associated with impaired functioning rather than clinical characteristics, a descriptive study.

Authors:  Trine V Lagerberg; Ole A Andreassen; Petter A Ringen; Akiah O Berg; Sara Larsson; Ingrid Agartz; Kjetil Sundet; Ingrid Melle
Journal:  BMC Psychiatry       Date:  2010-01-27       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.